Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The TLR4 antagonist Eritoran protects mice from lethal influenza infection.

Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN.

Nature. 2013 May 23;497(7450):498-502. doi: 10.1038/nature12118. Epub 2013 May 1.

2.

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group.

JAMA. 2013 Mar 20;309(11):1154-62. doi: 10.1001/jama.2013.2194.

PMID:
23512062
3.

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.

Aikawa N, Okubo Y, Lynn M, Rossignol DP, Wong YN, Schuck E, Kitahara Y, Nakano T, Sivak O, Wasan KM, Nagy C, Yen M.

Innate Immun. 2012 Dec;18(6):793-803. doi: 10.1177/1753425912441845. Epub 2012 Mar 29.

PMID:
22459966
4.

Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.

Mita M, Kelly KR, Mita A, Ricart AD, Romero O, Tolcher A, Hook L, Okereke C, Krivelevich I, Rossignol DP, Giles FJ, Rowinsky EK, Takimoto C.

Clin Cancer Res. 2011 Jan 1;17(1):193-200. doi: 10.1158/1078-0432.CCR-10-0010.

5.

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.

Rossignol DP, Wong N, Noveck R, Lynn M.

Innate Immun. 2008 Dec;14(6):383-94. doi: 10.1177/1753425908099173.

PMID:
19039062
6.

Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

Wasan KM, Risovic V, Sivak O, Lee SD, Mason DX, Chiklis GR, McShane J, Lynn M, Wong N, Rossignol DP.

Pharm Res. 2008 Jan;25(1):176-82. Epub 2007 Sep 12.

PMID:
17849177
7.

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.

Bennett-Guerrero E, Grocott HP, Levy JH, Stierer KA, Hogue CW, Cheung AT, Newman MF, Carter AA, Rossignol DP, Collard CD.

Anesth Analg. 2007 Feb;104(2):378-83.

PMID:
17242095
8.

TLR4 antagonists for endotoxemia and beyond.

Rossignol DP, Lynn M.

Curr Opin Investig Drugs. 2005 May;6(5):496-502. Review.

PMID:
15912963
9.

Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M.

Antimicrob Agents Chemother. 2004 Sep;48(9):3233-40.

10.

Inhibition of endotoxin response by synthetic TLR4 antagonists.

Hawkins LD, Christ WJ, Rossignol DP.

Curr Top Med Chem. 2004;4(11):1147-71. Review.

PMID:
15279606
11.

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].

Lynn M, Wong YN, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG, Wasan KM, Rossignol DP.

J Pharmacol Exp Ther. 2004 Jan;308(1):175-81. Epub 2003 Oct 17. Erratum in: J Pharmacol Exp Ther. 2004 Feb;308(2):796.

PMID:
14566003
12.

Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Wasan KM, Sivak O, Cote RA, MacInnes AI, Boulanger KD, Lynn M, Christ WJ, Hawkins LD, Rossignol DP.

Antimicrob Agents Chemother. 2003 Sep;47(9):2796-803.

13.
14.

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.

Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP.

J Pharmacol Exp Ther. 2003 Mar;304(3):1093-102.

PMID:
12604686
15.

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.

Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG.

J Infect Dis. 2003 Feb 15;187(4):631-9. Epub 2003 Feb 7.

PMID:
12599080
16.

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.

Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, Yang H, Rossignol DP, Nault A, Rose J, Przetak M, Chow JC, Gusovsky F.

J Pharmacol Exp Ther. 2002 Feb;300(2):655-61.

PMID:
11805229
17.

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL.

J Clin Invest. 2001 Jun;107(12):1581-9.

18.

Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, Wasan KM, Peteherych K, Rossignol DP.

Antimicrob Agents Chemother. 2000 Mar;44(3):504-10.

19.

Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Wasan KM, Strobel FW, Parrott SC, Lynn M, Christ WJ, Hawkins LD, Rossignol DP.

Antimicrob Agents Chemother. 1999 Oct;43(10):2562-4.

20.

E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Kawata T, Bristol JR, Rossignol DP, Rose JR, Kobayashi S, Yokohama H, Ishibashi A, Christ WJ, Katayama K, Yamatsu I, Kishi Y.

Br J Pharmacol. 1999 Jun;127(4):853-62.

21.

Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist.

Kobayashi S, Kawata T, Kimura A, Miyamoto K, Katayama K, Yamatsu I, Rossignol DP, Christ WJ, Kishi Y.

Antimicrob Agents Chemother. 1998 Nov;42(11):2824-9.

22.

Induction of lipopolysaccharide-binding protein gene expression in cultured rat pulmonary artery smooth muscle cells by interleukin 1 beta.

Wong HR, Pitt BR, Su GL, Rossignol DP, Steve AR, Billiar TR, Wang SC.

Am J Respir Cell Mol Biol. 1995 Apr;12(4):449-54.

PMID:
7695925
24.

Anti-endotoxin activity of a novel synthetic lipid A analog.

Kawata T, Bristol JR, Rose JR, Rossignol DP, Christ WJ, Asano O, Dubuc GR, Gavin WE, Hawkins LD, Kishi Y, et al.

Prog Clin Biol Res. 1995;392:499-509.

PMID:
8524958
25.

Suppression of lipopolysaccharide-induced macrophage nitric oxide and cytokine production in vitro by a novel lipopolysaccharide antagonist.

Wang SC, Rossignol DP, Christ WJ, Geller DA, Freeswick PD, Thai NL, Su GL, Simmons RL.

Surgery. 1994 Aug;116(2):339-46; discussion 446-7.

PMID:
7519366
26.

Pumiliotoxin alkaloids: a new class of sodium channel agents.

Daly JW, Gusovsky F, McNeal ET, Secunda S, Bell M, Creveling CR, Nishizawa Y, Overman LE, Sharp MJ, Rossignol DP.

Biochem Pharmacol. 1990 Jul 15;40(2):315-26.

PMID:
2165404
27.

Pumiliotoxin B binds to a site on the voltage-dependent sodium channel that is allosterically coupled to other binding sites.

Gusovsky F, Rossignol DP, McNeal ET, Daly JW.

Proc Natl Acad Sci U S A. 1988 Feb;85(4):1272-6.

28.

Characterization of the Strongylocentrotus purpuratus egg cell surface receptor for sperm.

Ruiz-Bravo N, Rossignol DP, Decker GL, Rosenberg LI, Lennarz WJ.

Adv Exp Med Biol. 1986;207:293-313.

PMID:
3825683
29.

Rat cauda epididymal fluid is a mucus.

Usselman MC, Cone RA, Rossignol DP.

J Androl. 1985 Sep-Oct;6(5):315-20.

30.

Characterization of the sperm receptor on the surface of eggs of Strongylocentrotus purpuratus.

Rossignol DP, Earles BJ, Decker GL, Lennarz WJ.

Dev Biol. 1984 Aug;104(2):308-21.

PMID:
6086427
31.

Induction of calcium-dependent, localized cortical granule breakdown in sea-urchin eggs by voltage pulsation.

Rossignol DP, Decker GL, Lennarz WJ, Tsong TY, Teissie J.

Biochim Biophys Acta. 1983 Dec 19;763(4):346-55.

PMID:
6652114
32.

Metabolic interconversion of dolichol and dolichyl phosphate during development of the sea urchin embryo.

Rossignol DP, Scher M, Waechter CJ, Lennarz WJ.

J Biol Chem. 1983 Aug 10;258(15):9122-7.

33.

The molecular basis of sperm-egg interaction in the sea urchin.

Rossignol DP, Lennarz WJ.

Ciba Found Symp. 1983;98:268-96.

PMID:
6315319
34.

Induction of phosphorylation of dolichol during embryonic development of the sea urchin.

Rossignol DP, Lennarz WJ, Waechter CJ.

J Biol Chem. 1981 Oct 25;256(20):10538-42. No abstract available.

35.

Sperm-egg binding: identification of a species-specific sperm receptor from eggs of Stronglyocentrotus purpuratus.

Rossignol DP, Roschelle AJ, Lennarz WJ.

J Supramol Struct Cell Biochem. 1981;15(4):347-58.

PMID:
7299835
36.

L-Proline site for triggering Bacillus megaterium spore germination.

Rossignol DP, Vary JC.

Biochem Biophys Res Commun. 1979 Jul 27;89(2):547-51. No abstract available.

PMID:
114177
37.
38.

A unique method for studying the initiation of Bacillus megaterium spore germination.

Rossignol DP, Vary JC.

Biochem Biophys Res Commun. 1977 Dec 21;79(4):1098-103. No abstract available.

PMID:
23775

Supplemental Content

Loading ...
Support Center